Research suggests GHK-CU has a relatively short half-life, making twice-daily administration theoretically superior for sustained gene expression effects
It also plays an important role in maintaining healthy skin, eyes, and nerves
Factors like stress, poor gut health, or certain medications can reduce absorption even further
Garveys contributions to combination therapy research include: REDEFINE 1 trial leadership Guiding the pivotal Phase 3 trial demonstrating 20.4% mean weight loss with the combination Metabolic disease pathophysiology Extensive research on insulin resistance, adipose tissue biology, and energy metabolism Clinical trial design Decades of experience leading multi-center obesity and diabetes trials Translational research Bridging basic metabolic research with clinical application Guideline development Contributing to professional society guidelines for obesity and diabetes management His work has been instrumental in establishing combination therapy approaches as the next generation of obesity pharmacotherapy, demonstrating that targeting multiple complementary pathways can produce weight loss approaching bariatric surgery outcomes
The same central and peripheral mechanisms that suppress appetite can trigger nausea, vomiting, and early satiety as off-target effects